Circulating Tumour Cells in the Prediction of Bone Metastasis

Bone is the most common organ for the development of metastases in many primary tumours, including those of the breast, prostate and lung. In most cases, bone metastasis is incurable, and treatment is predominantly palliative. Much research has focused on the role of Circulating Tumour Cells (CTCs)...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-01, Vol.16 (2), p.252
Main Authors: Choi, Siu-Wai, Sun, Aria Kaiyuan, Cheung, Jason Pui-Yin, Ho, Jemmi Ching-Ying
Format: Article
Language:English
Subjects:
Blood
Bone cancer
Bone marrow
Bone tumors
Breast
Breast cancer
Care and treatment
Cell surface
Denosumab
Development and progression
Disease spread
FDA approval
Health aspects
Lung cancer
Medical prognosis
Medical research
Medicine, Experimental
Metastases
Metastasis
Neuroendocrine tumors
Palliation
Patients
Peripheral blood
Prostate
Prostate cancer
Scintigraphy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bone is the most common organ for the development of metastases in many primary tumours, including those of the breast, prostate and lung. In most cases, bone metastasis is incurable, and treatment is predominantly palliative. Much research has focused on the role of Circulating Tumour Cells (CTCs) in the mechanism of metastasis to the bone, and methods have been developed to isolate and count CTCs from peripheral blood. Several methods are currently being used in the study of CTCs, but only one, the CellSearchTM system has been approved by the United States Food and Drug Administration for clinical use. This review summarises the advantages and disadvantages, and outlines which clinical studies have used these methods. Studies have found that CTC numbers are predictive of bone metastasis in breast, prostate and lung cancer. Further work is required to incorporate information on CTCs into current staging systems to guide treatment in the prevention of tumour progression into bone.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16020252